Oncology Center for Excellence (OCE) Regulatory Programs

June 2022

Tamy Kim, PharmD
Director for Regulatory Policy and Affairs, OCE

About Oncology Center for Excellence (OCE)

FDA U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE



- Established on January 20, 2017
- Created in response to the National Cancer Moonshot Initiative
- Authorized by the **21st Century Cures Act:** 1st FDA Inter-center Institute

Historical Context of FDA and OCE Programs



FDA Oncology Metrics:

- **Accelerated Approval:** 84% of FDA accelerated approvals from 2010-2019 were for oncology indications
- **Priority Review Designation** (2015-2020) for oncology approvals: 88% of NME approvals, 82% of efficacy supplement (new indication) approvals
- **Breakthrough Therapy Designation** (2020): 43% of CDER BTDs for oncology indications

Summary of OCE Review Programs

FDA U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE

	Real-Time Oncology Review (RTOR)	Assessment Aid	Project Orbis
Start Date	February 2018	April 2018	May 2019
Objective	Increase efficiency of review through earlier submission of critical efficacy and safety data	Focus review on critical assessment, decrease administrative time	Facilitate faster patient access to innovative cancer therapies in participating countries
Key Elements	Early submission of datasets	Template with distinct sections for data, Applicant position and FDA Assessment	Direct collaboration between FDA and partner countries
Qualifying Criteria	Substantial improvement over available therapy Straightforward study designs and well-understood endpoints	Any oncology drug application	High impact and clinically significant applications

OCE's Real-Time Oncology Review (RTOR)

FDA U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE

- RTOR:
  - Program initiated by OCE in 2018 to facilitate earlier review of applications addressing unmet need in oncology
  - Facilitates earlier submission of topline results and datasets to support earlier start to FDA review
  - Facilitates safe and effective treatments to patients as early as possible
- RTOR eligibility criteria:
  - Drugs likely to demonstrate substantial improvements over available therapy or meeting criteria for Expedited Programs.
  - Straight forward study designs.
  - Endpoints that can be easily interpreted.
- Involves early engagement with applicant to discuss submission timelines for RTOR components
- FDA will also consider whether adequate dose optimization has been performed to support the proposed dosage

OCE's Real-Time Oncology Review (RTOR) Experience

Completed analysis of a 2-year experience (February 2018-April 2020)

FDA U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE

- 20 approvals in 2-year experience (18 supplements, 2 NMEs)
- Median time-to-approval from submission: 3.3 months (range 0.4 to 5.9)
- Median RTOR lead time: 5.7 weeks (range 1.7 to 16.2)
- All applications received priority review and nine (45%) received breakthrough therapy designation status.

OCE's Assessment Aid

- Voluntary submission from the applicant to facilitate FDA's assessment of NDA/BLAs, including supplements.
- The Assessment Aid is based on the OCE's Multidisciplinary Review template
  - ➢ Focus the FDA review on critical thinking and
  - ➢ Increase review efficiency and consistency and decrease review time spent on administrative tasks

Content of OCE's Assessment Aid

- The Assessment Aid consists of:
  - ➢Data from the applicant (completed by applicant)
  - ➢The applicant's position (completed by applicant)
  - ➢FDA's Assessment (completed by FDA)
    - ❖FDA will focus on whether FDA agrees with the applicant's position

Examples of OCE Assessment Aids

FDA U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE

- BLA 761137 (enfortumab vedotin-ievx)
- NDA 212526 (alpelisib)
- sNDA 210259/S-6 (acalabrutinib)
- sBLA 208558/S-13 (venetoclax)
- NDA 761049Orig1s009 (avelumab)
- NDA 208573Orig1s020 (venetoclax)

FDA Oncology Global Collaboration

FDA U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE

- Began in October 2004 with European Medicines Agency (EMA)
- **Expanded Oncology Cluster to other Regulatory Authorities:**
  - January 2010: Health Canada (HC)
  - January 2014: Pharmaceuticals and Medical Devices Agency (PMDA) (Japan)
  - July 2014: Therapeutic Goods Administration (TGA) (Australia)
  - July 2016: Swissmedic (SMC) (Switzerland)
- **Project Orbis:** Collaborative Review Program
  - Launched in May 2019
  - Current participating countries (Project Orbis Partners): Australia, Brazil, Canada, Israel, Singapore, Switzerland, United Kingdom

Requirements for Project Orbis Countries

FDA U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE

- Confidentiality agreement with all other Orbis countries
- Application submission in English language with Sponsor authorization letter to share information across Orbis countries
- Availability to participate in meetings
  - Product-Specific
  - General: Quarterly

Project Orbis Overview

FDA U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE

- **Application Selection Process**: FDA serves as primary coordinator. Plan for concurrent or near-concurrent submissions across participating countries
  - **Assessment Aid:** primary review document for FDA and core reference document for Orbis countries
- **Review:** multi-country teleconferences (2-3 per application)
  - each country retains full independence in regulatory decision and labeling negotiations

Key Features of Project Orbis

FDA U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE

- **Leverages FDA staffing and expertise with application review**
  - **FDA Oncology Staff:** 250+ full-time (100 oncologists + 10 clinical analysts, 30 statisticians, 30 clinical pharmacologists, 30 nonclinical, 70 project managers)
  - **FDA Disease-Specific Teams**: 17

Breast-Gynecologic (2)	Genitourinary (2)	Thoracic/Head-Neck (2)
Gastrointestinal (2)	Melanoma/Sarcoma	Pediatric/Neuro-oncology (2)
Leukemia/Transplant (3)	Lymphoma (2)	Myeloma

  - FDA review provides for independent multi-disciplinary assessment including full review of datasets.
- **Not a work-sharing initiative**
- **Each country retains independent decision-making for each application**

Project Orbis 2-Year Update

FDA U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE

	Submitted	Action
FDA	58	44
HC	36	20
TGA	33	14
SMC	21	11
HSA	11	6
ANVISA	11	4
MHRA	11	1
Total	**181**	**100**



Oncology Center of Excellence- What We are About

U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE



Oncology Center of Excellences' Programs and Initiatives

- Immuno-Oncology
- Oncology Cell and Gene Therapy
- Oncology Device and Diagnostics
- Oncology Regulatory Affairs and Policy
- Patient-Focused Drug Development
- Pediatric Oncology
- Precision Oncology
- Oncology Real World Evidence
- Rare Cancers Program
- Real-Time Oncology Review (RTOR)
- OCE Summer Scholars
- Project Orbis
- Project Optimus
- Project Facilitate
- Project Confirm
- Project Renewal
- Project Livin' Label
- Project Socrates
- Project Accelerate
- Project Point/Counterpoint
- Project Protect
- Project Patient Voice
- Project SignifiCanT
- Project Equity
- Project Community
- Project Silver
- Project Post Covidity

Learn more at https://www.fda.gov/about-fda/fda-organization/oncology-center-excellence and https://www.fda.gov/media/145613/download

Acknowledgements

- Richard Pazdur
- Julia Beaver
- Angelo DeClaro
- Dianne Spillman
- Jenny Gao
- Pamela Balcazar
- Jennie Lee

FDA U.S. FOOD & DRUG ADMINISTRATION
ONCOLOGY CENTER OF EXCELLENCE

FDA Oncology
@FDAOncology